Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. FABHALTA (iptacopan)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

FABHALTA (iptacopan)

Medicine - Posted on Nov 27 2024
Active substance (DCI)
  • iptacopan
history (2)
  • Economic analysis
    10/9/24

    FABHALTA (iptacopan) - Paroxysmal nocturnal haemoglobinuria (PNH)

    Summary of opinion Favourable opinion for reimbursement only in “the treatment of adult patients with paroxysmal nocturnal h...
    CAV :
    54321
    icône flèche
  • 5/2/24

    FABHALTA (iptacopan) - Hémoglobinurie paroxystique nocturne

    Autorisation d’accès précoce octroyée à la spécialité FABHALTA (iptacopan) dans l'indication « en monothérapie dans le trait...
    icône flèche
Technical information
ATC code
  • L04AJ08
Manufacturer
NOVARTIS PHARMA
Presentation

FABHALTA 200 mg, gélule
plaquette(s) PVC polyéthylène PVDC aluminium de 56 gélule(s) (CIP : 34009 302 946 2 8)

All our publications
    Anemia and hemoglobinopathies Congenital, genetic and rare diseases Drug therapy Hematologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
qGTvcJzTpcxH4dG5